CN Patent

CN119019375A — 一种瑞司美替罗新晶型及其制备方法

Assigned to Aoruite Pharmaceutical Tianjin Co ltd · Expires 2024-11-26 · 1y expired

What this patent protects

本发明提供了一种瑞司美替罗新晶型，晶型APTI‑I，使用Cu‑Kα辐射，其以2θ角度表示的X射线粉末衍射图谱在5.0°±0.2°、6.3°±0.2°、7.8°±0.2°、12.2°±0.2°、20.0°±0.2°处有特征峰。该晶型易制备、纯度高、稳定性好，水溶媒中溶解度好，适合工业放大生产和制备药物制剂。

USPTO Abstract

本发明提供了一种瑞司美替罗新晶型，晶型APTI‑I，使用Cu‑Kα辐射，其以2θ角度表示的X射线粉末衍射图谱在5.0°±0.2°、6.3°±0.2°、7.8°±0.2°、12.2°±0.2°、20.0°±0.2°处有特征峰。该晶型易制备、纯度高、稳定性好，水溶媒中溶解度好，适合工业放大生产和制备药物制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN119019375A
Jurisdiction
CN
Classification
—
Expires
2024-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Aoruite Pharmaceutical Tianjin Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.